Makoto Kubo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/478905/publications.pdf

Version: 2024-02-01

43	1,103	516215	414034
papers	citations	16 h-index	32 g-index

46	46	46	1620
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan. Breast Cancer, 2022, 29, 1-8.	1.3	6
2	Genetic medicine is accelerating in Japan. Breast Cancer, 2022, 29, 659-665.	1.3	5
3	Surgical treatment trends and identification of primary breast tumors after surgery in occult breast cancer: a study based on the Japanese National Clinical Databaseâ€"Breast Cancer Registry. Breast Cancer, 2022, 29, 698-708.	1.3	8
4	Lymph Nodes as Anti-Tumor Immunotherapeutic Tools: Intranodal-Tumor-Specific Antigen-Pulsed Dendritic Cell Vaccine Immunotherapy. Cancers, 2022, 14, 2438.	1.7	6
5	Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites. Immunological Investigations, 2021, 50, 562-579.	1.0	29
6	Comprehensive molecular profiling broadens treatment options for breast cancer patients. Cancer Medicine, 2021, 10, 529-539.	1.3	23
7	FoundationOneÂ® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience. Surgery Today, 2021, 51, 619-626.	0.7	9
8	Surgical treatment for breast cancer in a patient with erythropoietic protoporphyria and photosensitivity: a case report. Surgical Case Reports, 2021, 7, 1.	0.2	5
9	Validity of the prognostication tool PREDICT version 2.2 in Japanese breast cancer patients. Cancer Medicine, 2021, 10, 1605-1613.	1.3	7
10	Neoantigens elicit T cell responses in breast cancer. Scientific Reports, 2021, 11, 13590.	1.6	17
11	Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis. Anticancer Research, 2021, 41, 4101-4115.	0.5	3
12	Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive Breast Cancer. Anticancer Research, 2021, 41, 4143-4149.	0.5	1
13	Current Status and Problems of Breast Cancer Treatment with Schizophrenia. Clinical Breast Cancer, 2021, , .	1.1	7
14	Microsatellite instability in Japanese female patients with triple-negative breast cancer. Breast Cancer, 2020, 27, 490-498.	1.3	28
15	Annual report of the Japanese Breast Cancer Registry for 2017. Breast Cancer, 2020, 27, 803-809.	1.3	30
16	Annual report of the Japanese Breast Cancer Society registry for 2016. Breast Cancer, 2020, 27, 511-518.	1.3	24
17	Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer. Chinese Clinical Oncology, 2020, 9, 33-33.	0.4	7
18	Effects of Diluent Volume and Administration Time on the Incidence of Anaphylaxis Following Docetaxel Therapy in Breast Cancer. Biological and Pharmaceutical Bulletin, 2020, 43, 663-668.	0.6	2

#	Article	IF	Citations
19	Breast metastasis from pelvic high-grade serous adenocarcinoma: a report of two cases. Surgical Case Reports, 2020, 6, 317.	0.2	1
20	Usefulness of the nCounter Analysis System to Monitor Immune-related Biomarkers in PBMCs During Anti-PD-1 Therapy. Anticancer Research, 2019, 39, 4517-4523.	0.5	1
21	A population-based recurrence risk management study of patients with pT1 node-negative HER2+â€‰breast cancer: a National Clinical Database study. Breast Cancer Research and Treatment, 2019, 178, 647-656.	1.1	16
22	T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer. Breast Cancer Research and Treatment, 2019, 176, 569-577.	1.1	18
23	Cardioprotective effect of reninâ€“angiotensin inhibitors and Î²-blockers in trastuzumab-related cardiotoxicity. Clinical Research in Cardiology, 2019, 108, 1128-1139.	1.5	9
24	QOL-enhancing surgery for patients with HER2-positive metastatic breast cancer. BMJ Supportive and Palliative Care, 2019, 9, 151-154.	0.8	4
25	Effects of menstrual cycle on background parenchymal enhancement and detectability of breast cancer on dynamic contrast-enhanced breast MRI: A multicenter study of an Asian population. European Journal of Radiology, 2019, 110, 130-135.	1.2	11
26	Efficacy and Safety of Bi-weekly Pegfilgrastim for Dose-dense Chemotherapy-induced Neutropenia in Breast Cancer Patients. Anticancer Research, 2018, 38, 4381-4386.	0.5	2
27	Visualizing Energy Charge in Breast Carcinoma Tissues by MALDI Mass-spectrometry Imaging Profiles of Low-molecular-weight Metabolites. Anticancer Research, 2018, 38, 4267-4272.	0.5	10
28	BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations. Clinical Breast Cancer, 2018, 18, e1217-e1227.	1.1	7
29	Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines. Anticancer Research, 2018, 38, 4273-4279.	0.5	21
30	The effects of anesthetic agents on pupillary function during general anesthesia using the automated infrared quantitative pupillometer. Journal of Clinical Monitoring and Computing, 2017, 31, 291-296.	0.7	45
31	The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Oncotarget, 2017, 8, 15584-15592.	0.8	101
32	Metastatic Collision Tumors Consisting of Sigmoid Colon Cancer and Breast Cancer. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2017, 78, 2551-2557.	0.0	0
33	BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer. PLoS ONE, 2016, 11, e0167016.	1.1	23
34	Insulin-like growth factor II messenger RNA-binding protein-3 is an indicator of malignant phyllodes tumor of the breast. Human Pathology, 2016, 55, 30-38.	1.1	12
35	CD24 suppresses malignant phenotype by downregulation of SHH transcription through STAT1 inhibition in breast cancer cells. Cancer Letters, 2016, 374, 44-53.	3.2	41
36	Utility of adaptive control processing for the interpretation of digital mammograms. Acta Radiologica, 2016, 57, 1297-1303.	0.5	2

#	Article	IF	Citations
37	Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer. Annals of Pharmacotherapy, 2014, 48, 1159-1165.	0.9	23
38	Differentiation between benign phyllodes tumors and fibroadenomas of the breast on MR imaging. European Journal of Radiology, 2014, 83, 1344-1349.	1.2	30
39	Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. Anticancer Research, 2012, 32, 2331-6.	0.5	37
40	A CASE OF MUCINOUS CARCINOMA OF THE BREAST AFTER A ONE-YEAR HORMONE REPLACEMENT THERAPY. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2006, 67, 587-591.	0.0	0
41	Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production. Cancer Immunology, Immunotherapy, 2005, 54, 468-476.	2.0	30
42	Hedgehog Signaling Pathway is a New Therapeutic Target for Patients with Breast Cancer. Cancer Research, 2004, 64, 6071-6074.	0.4	418
43	Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer. Anticancer Research, 2003, 23, 4443-9.	0.5	21